Health Care & Life Sciences » Biotechnology | Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
47.00
73.00
249.00
16,199.00
902.00
662
SG&A Expense
18,079.00
38,619.00
48,607.00
54,300.00
66,623.00
56,829
EBIT
18,169.00
38,752.00
48,846.00
38,757.00
66,467.00
56,599
Non Operating Income/Expense
68.00
71.00
39.00
33.00
41.00
3
Interest Expense
-
-
105.00
80.00
50.00
11
Pretax Income
18,226.00
38,642.00
48,555.00
38,389.00
65,984.00
59,881
Consolidated Net Income
18,226.00
38,642.00
48,555.00
38,389.00
65,984.00
59,881
Net Income
18,226.00
38,642.00
48,555.00
38,389.00
65,984.00
59,881
Net Income After Extraordinaries
18,226.00
38,642.00
48,555.00
38,389.00
65,984.00
59,881
Net Income Available to Common
21,092.00
39,161.00
48,555.00
38,389.00
65,984.00
59,881
EPS (Basic)
3.84
3.76
3.36
2.40
3.36
2.25
Basic Shares Outstanding
5,488.30
10,353.40
14,386.50
15,949.60
19,674.80
26,601
EPS (Diluted)
3.84
3.78
3.38
2.41
3.35
2.25
Diluted Shares Outstanding
5,488.30
10,353.40
14,386.50
15,949.60
19,674.80
26,601
EBITDA
18,032.00
38,546.00
48,358.00
38,101.00
65,721.00
56,167
Non-Operating Interest Income
11.00
39.00
357.00
415.00
574.00
1,089
Preferred Dividends
2,866.00
519.00
-
-
-
-

About Idera Pharmaceuticals

View Profile
Address
505 Eagleview Boulevard
Exton Pennsylvania 19341
United States
Employees -
Website http://www.iderapharma.com
Updated 07/08/2019
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.